3B Blackbio Dx Limited strategy deck summary

Strategy deck of 14 Aug 2025, summarised by AI from the filing.

3B BlackBio Q1 2025-26 consolidated revenue ₹2,223.46 cr, PAT ₹1,264.45 cr; MDx India growth guided at 15%–20% for FY 2025–26.

Key takeaways

1. Q1 results Consolidated revenue from operations ₹2,223.46 cr (Q1 2024-25: ₹1,943.40 cr); PAT ₹1,264.45 cr (Q1 2024-25: ₹1,129.76 cr).
2. Growth driver TRUPCR Europe Limited sales grew to GBP 380,477 in Q1 FY 2025-26 from GBP 309,204, driven by Made in UK products and European traction.
3. Risk Increasing competition puts pressure on margins; geopolitical issues in Middle East and Ukraine may affect sales.

Original filing on BSE

3B Blackbio Dx Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (13 Aug 2026)
• Q4 FY26: Earnings call (1 Jun 2026), Results deck (29 May 2026)
• Q3 FY26: Earnings call (21 Feb 2026), Results deck (6 Feb 2026)
• Q2 FY26: Results deck (13 Nov 2025)
• Q1 FY26: Earnings call (19 Aug 2025)
• Q4 FY25: Results deck (28 May 2025)
• Other events: Strategy deck (14 Aug 2025)